Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):946-948. doi: 10.1051/medsci/2019226. Epub 2020 Jan 6.

[The revolution of immuno-oncology therapy: specificities for the physicians].

[Article in French; Abstract available in French from the publisher]

Author information

1
Service de Dermatologie, CHU Lille, Lille, France.
2
Service de Pneumologie et Oncologie Thoracique, CHU Lille, Lille France.
3
Service de Pneumologie et Oncologie Thoracique, CHU Lille, Lille France - Université de Lille, Lille, France - Unité Inserm 1189 OncoThAI, Lille, France.
4
Service de Dermatologie, CHU Lille, Lille, France - Université de Lille, Lille, France - Unité Inserm 1189 OncoThAI, Lille, France.

Abstract

in English, French

The use of immune checkpoint inhibitors has revolutionized the treatment and prognosis of many cancer patients. Associated with the raise of these new treatments, new side effects have been observed, requiring specific management. In addition, the tumor evolution and its monitoring under immunotherapy differ from conventional treatments, and require an adaptation of the radiological criteria for tumor lesions monitoring. Many other therapeutic targets exist and could potentially be associated with immune checkpoint inhibitors. Many challenges still need to be overcome in order to better understand and optimize the use of these new molecules.

PMID:
31903898
DOI:
10.1051/medsci/2019226

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center